Abstract
It has been well documented that the common target of quinolone antibacterials is the bacteria-specific type II DNA topoisomerase, i.e. DNA gyrase (for reviews, see Cozzarelli 1980; Geliert 1981; Wang 1985; Drlica and Franco 1988). These drugs share a common mode of action with anti-cancer drugs by forming a ternary complex with the enzyme and the DNA substrate (Geliert et al. 1977; Sugino et al. 1977; Chen and Liu 1986; Glisson and Ross 1987). The biological consequence of the formation of such a “cleavable complex” is at least two-fold:
-
i)
the enzyme is inactivated, leading to the arrest of DNA synthesis in bacterial cells
-
ii)
the cleavable complex formation causes unrepairable DNA damage which is believed to trigger recA-dependent SOS repair response and alternatively leading to cell death, presumably by the expression of certain lethal proteins in the cell (Drlica 1984).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Chen GL, Liu LF (1986) DNA topoisomerases as therapeutic targets in cancer chemotherapy. Ann Reports in Med Chem 21:257–262
Chu DTW, Fernandes PB, Claiborne AK, Shen LL, Pernet AG (1988) Structure-activity relationships in quinolone antibacterials: design, synthesis and biological activities of novel isothiazoloquinolones. Drugs Exptl Clin Res 14:379–383
Cozzarelli NR (1980) DNA gyrase and the supercoiling of DNA. Science 207:953–960
Crumplin GC, Midgley JM, Smith JT (1980) Mechanism of action of nalidixic acid and its congeners. Topics in Antibiotic Chem 8:9–38
Drlica K (1984) Biology of bacterial deoxyribonucleic acid topoisomerases. Microbiol Reviews 48:273–289
Fernandes PB, Shen LL (1989) Quinolones: mode of action and mechanism of resistance. In: Actor P (ed) Clinical implications of antimicrobial resistance: mechanism, testing problems and epidemiology. the American Society of Microbiology, Eastern Pennsylvania Branch
Fu KP, Grace ME, McCloud SJ, Gregory FJ, Hung PP (1986) Discrepancy between the antibacterial activities and the inhibitory effects on Micrococcus luteus DNA gyrase of 13 quinolones. Chemotherapy 32:494–498
Geliert M, Mizuuchi K, O’Dea MH, Itoh T, Tomizawa J-I (1977) Proc Natl Acad Sci USA 74:4772–4776
Geliert M, Mizuuchi K, O’Dea MH, Ohmori H, Tomizawa J (1978) DNA gyrase and DNA supercoiling. Cold Spring Harbor Symp Quant Biol 43:35–40
Glisson BS, Ross WE (1987) Pharmac Ther 32:89–106
LeGoffic F (1985) Les quinolones, mécanisme d’action. In: Pocidalo JJ, Vachon F and Regnier B (eds) Les nouvelles quinolones. Editiones Amette, Paris pp. 15–23
Lilley DMJ (1980) The inverted repeat as a recognizable structure feature in supercoiled DNA molecules. Proc Natl Acad Sci USA 77:6468–6472
Marmur J, Doty P (1962) Determination of the base composition of deoxyribonucleic acid from its thermal denaturation temperature. J Mol Biol 5:109–118
Mizuuchi K, Mizuuchi M, Geliert M (1982) Cruciform structure on palindromic DNA are favored by DNA supercoiling. J Mol Biol 156:229–243
Palu’ G, Valisena S, Peracchi M, Palumbo M (1988) Do quinolones bind to DNA? Biochem Pharmacol 37:1887–1888
Panayotatos N, Wells RD (1981) Cruciform structures in Supercoiled DNA. Nature 289:466–470
Pommier Y, Covey JM, Kerrigan D, Markovitsm J, Pham R (1987) DNA unwinding and inhibition of mouse leukemia L1210 DNA topoisomerase I by intercalation. Nucleic Acids Res 15:6713–6731
Shen LL, Pernet AG (1985) Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA. Proc Natl Acad Sci USA 82:307–311
Shen LL, Baranowski J, Wai T (1986) Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug-DNA binding model. J. Cellular Biochemistry 1986; Suppl.10B: abstract of UCLA Symposium on DNA replication and recombination, Park City, Utah
Shen LL (1989) A reply: “Do quinolones bind to DNA?” — Yes. Biochem Pharmacol 38:2042–2044
Shen LL, Kohlbrenner WE, Weigl D and Baranowski J (1989a), Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes. J Biol Chem 264:2973–2978
Shen LL, Baranowski J, Pernet AG (1989b) Mechanism of inhibition of DNA gyrase by quinolone antibacterials. Specificity and cooperativity of drug binding to DNA. Biochemistry 28:2879–2885
Shen LL, Mitscher LA, Sharma PN, O’Donnell TJ, Chu DTW, Cooper CS, Rosen T, Pernet AG (1989c) Mechanism of inhibition of DNA gyrase by quinolone antibacterials. A cooperative drug-DNA binding model. Biochemistry 28:2886–2894
Shen LL, Baranowski J, Wai T, Chu DTW, Pernet AG (1989d) The binding of quinolones to DNA: should we worry about it? In: Fernandes PB (ed) The International Telesymposium on Quinolones, J.R. Prous Science Publishers, Barcelona, Spain, pp 159–170
Singleton CK, Wells RD (1982) Relationship between superhelical density and cruciform formation in Plasmid pVH 51. J Biol Chem 257:6292–6295
Sugino A, Peebles CL, Kreuzer KN, Cozzarelli NR (1977) Mechanism of action of nalidixic acid: purification of E. coli nalA gene product and its relationship to DNA gyrase and a novel cicking-closing enzyme. Proc Natl Acad Sci USA 74:4767–4771
Tomaletti S and Pedrini AM (1988) Studies on the interaction of 4-quinolones with DNA by DNA unwinding experiments. Biochim Biophy Acta 949:279–287
Wang JC (1985) DNA topoisomerases. Ann Rev Biochem 54:665–697
Zweerink MM, Edison A (1986) Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids. Antimicrob Agents and Chemother 29:598–601
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag London Limited
About this chapter
Cite this chapter
Shen, L.L. et al. (1990). Aspects of Quinolone-DNA Interactions. In: Crumplin, G.C. (eds) The 4-Quinolones: Anti Bacterial Agents in Vitro. Springer Series in Applied Biology. Springer, London. https://doi.org/10.1007/978-1-4471-3449-7_10
Download citation
DOI: https://doi.org/10.1007/978-1-4471-3449-7_10
Publisher Name: Springer, London
Print ISBN: 978-1-4471-3451-0
Online ISBN: 978-1-4471-3449-7
eBook Packages: Springer Book Archive